NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. The company is headquartered in Gaithersburg, Maryland and currently employs 6 full-time employees. The company went IPO on 2021-02-12. The firm is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The firm provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The firm is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Follow-Up Questions
Who is the CEO of Neximmune Inc?
Mr. Craig Jalbert is the President of Neximmune Inc, joining the firm since 2024.
What is the price performance of NEXI stock?
The current price of NEXI is $0.01, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Neximmune Inc?
Neximmune Inc belongs to Biotechnology industry and the sector is Health Care
What is Neximmune Inc market cap?
Neximmune Inc's current market cap is $13900
Is Neximmune Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Neximmune Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
